Pegvisomant normalises markers of bone turnover in acromegaly

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1424, 2004-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The place of pegvisomant in the management of acromegaly

By Parkinson Craig   Trainer Peter J  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 9, 2001-09 ,pp. : 1725-1735

Informa Healthcare

Access to resources Recommend Favorite

Pegvisomant shows potential in the treatment of acromegaly

By  

Inpharma, Vol. 1, Iss. 1235, 2000-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Pegvisomant modulates cortisol metabolism in acromegaly

By  

Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Long-term pegvisomant therapy promising in acromegaly

By  

Inpharma, Vol. 1, Iss. 1316, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease: Potential Uses and Pitfalls

By Cremers Serge   Garnero Patrick  

Drugs, Vol. 66, Iss. 16, 2006-01 ,pp. : 2031-2058

Adis International

Access to resources Recommend Favorite